


PG3602USw

In the claims:

1. (Currently Amended) A compound of formula (I)



or a pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide derivative thereof wherein

R^0 and R^1 are independently selected from the group consisting of H, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, and C_{1-6} alkoxy substituted by one or more fluorine atoms;

R^2 is selected from the group consisting of H, C_{1-6} alkyl, C_{1-6} alkyl substituted by one or more fluorine atoms, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, SC_{1-6} alkyl, $C(O)H$, $C(O)C_{1-6}$ alkyl, C_{1-6} alkylsulphonyl, and C_{1-6} alkoxy substituted by one or more fluorine atoms; and

R^3 is C_{1-6} alkyl or NH_2 .

2. (Previously Presented) A compound as claimed in claim 1 wherein R^0 and R^1 are independently selected from the group consisting of H, halogen, C_{1-6} alkyl, and C_{1-6} alkoxy; R^2 is C_{1-3} alkyl substituted by one or more fluorine atoms; and R^3 is C_{1-3} alkyl or NH_2 .

3. (Previously Presented) A compound as claimed in claim 1 wherein R^0 and R^1 are independently selected from the group consisting of H, F, Cl, C_{1-3} alkyl, and C_{1-3} alkoxy; R^2 is C_{1-3} alkyl substituted by one or more fluorine atoms; and R^3 is methyl or NH_2 .

PG3602USw

4. (Previously Presented) A compound as claimed in claim 1 wherein R^0 is selected from the group consisting of F, Cl, C_{1-3} alkyl and C_{1-3} alkoxy; R^1 is H; R^2 is C_{1-3} alkyl substituted by one or more fluorine atoms; and R^3 is methyl or NH_2 .
5. (Previously Presented) A compound as claimed in claim 1 wherein R^0 is at the 3- or 4- position of the phenyl ring; and R^2 is at the 6- position of the pyridine ring.
6. (Currently Amended) A compound selected from the group consisting of:
- 4-[2-(3-fluoro-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-benzenesulfonamide;
 - 2-(3-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridine;
 - 4-[2-(4-ethoxy-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-benzenesulfonamide;
 - 4-[2-(4-fluoro-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-benzenesulfonamide;
 - 2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridine;
 - 4-(2-phenyl-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl)-benzenesulfonamide;
 - 3-(4-methanesulfonyl-phenyl)-2-phenyl-6-trifluoromethyl-pyrazolo[1,5-a]pyridine;
 - 4-[2-(4-methyl-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-benzenesulfonamide;
- or a pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide derivative thereof.

PG3602USw

7. (Previously Presented) A compound selected from the group consisting of:

N-acetyl-4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;

N-acetyl-4-[2-(4-ethoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;

N-acetyl-4-[2-phenyl-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;

sodium salt of N-acetyl-4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;

4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-methoxyacetyl)benzenesulfonamide;

4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propionylbenzenesulfonamide;

4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-isobutyrylbenzenesulfonamide;

N-benzoyl-4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;

methyl 4-[[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl)sulfonyl]amino]-4-oxobutanoate;

4-[[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl)sulfonyl]amino]-4-oxobutanoic acid;

4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentanoylbenzenesulfonamide;

2-[[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl)sulfonyl]amino]-2-oxoethyl acetate;

N-acetyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;

N-(2-chloroacetyl)-4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;

N-[2-(diethylamino)acetyl]-4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;

PG3602USw

methyl {4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl}sulfonylcarbamate; and
tert-butyl {4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl}sulfonylcarbamate.

8. (Currently Amended) A compound selected from the group consisting of:


4-[6-chloro-2-(3-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
6-chloro-2-(3-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridine;
4-[6-methyl-2-phenyl-pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
4-[2-(3-fluorophenyl)-6-methyl-pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
4-[2-(3-ethoxyphenyl)-6-methyl-pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
4-[2-(4-ethoxyphenyl)-6-methyl-pyrazolo[1,5-a]pyridin-3-yl]benzenesulfonamide;
6-methyl-2-phenyl-3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridine;
2-(3-fluorophenyl)-6-methyl-3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridine;
2-(3-ethoxyphenyl)-6-methyl-3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridine;
2-(4-ethoxyphenyl)-6-methyl-3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridine;

or a pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide derivative thereof.


9. (Currently Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

PG3602USw

(A) reacting a compound of formula (II)



or a protected derivative thereof, with a compound of formula (III)



or a protected derivative thereof to prepare a compound of formula (I);

and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide ~~derivative~~ thereof.

10. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more physiologically acceptable carriers or excipients.


11.-16. Canceled.

17. (Previously Presented) The compound according to claim 1, wherein R⁰ is selected from the group consisting of F, Cl, methyl and ethoxy; R¹ is H; R² is trifluoromethyl; and R³ is methyl or NH₂.

18. (Currently Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) where R³ represents C₁₋₄alkyl, reacting a compound of formula (IV)

PG3602USw




or a protected derivative thereof with an oxidising agent to prepare a compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide derivative thereof.

19. (Currently Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) where R² is C₁₋₆alkylsulphonyl, oxidising a compound of formula (V)




or a protected derivative thereof to prepare a compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide derivative thereof.

20. (Currently Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

PG3602USw

(A) where R^2 is C_{1-6} alkoxy substituted by one or more fluorine atoms, reacting a alcohol of formula (VI)




or a protected derivative thereof with a halofluoroalkane to prepare a compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide derivative thereof.

21. (Currently Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) where R^3 is NH_2 , reacting a compound of formula (X)



with a source of ammonia under conventional conditions to prepare a compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide derivative thereof.

PG3602USw

22. (Currently Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) interconverting a compound of formula (I) into another compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide derivative thereof.

23. (Currently Amended) A process for the preparation of a compound as claimed in claim 1, said process comprising the steps of:

(A) deprotecting a protected derivative of compound of formula (I); and

(B) optionally converting the compound of formula (I) to a pharmaceutically acceptable salt, solvate, ester or amide, or salt or solvate of such ester or amide derivative thereof.

24. Canceled.

25. Canceled.

26. (Currently Amended) A method for the ~~prophylaxis or treatment~~ of a human subject suffering from a condition or disease selected from the group consisting of pain, fever and inflammation, said method comprising administering an effective amount of a compound as claimed in claim 1.

27. Canceled.

28. (Currently Amended) A method for the ~~prophylaxis or treatment~~ of a human subject suffering from pain, said method comprising administering an effective amount of a compound of formula (I) as claimed in claim 1.

PG3602USw

29. (Currently Amended) A method for the ~~prophylaxis or treatment~~ of a human subject suffering from arthritis, said method comprising administering an effective amount of a compound of formula (I) as claimed in claim 1.

30. – 34. Canceled.

35. (Previously Presented) 4-[2-(3-fluoro-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-benzenesulfonamide.

36. (New) A method for the treatment of a human subject suffering from lower back pain, said method comprising administering an effective amount of a compound as claimed in claim 1.

37. (New) A method for the treatment of a human subject suffering from neck pain, said method comprising administering an effective amount of a compound as claimed in claim 1.

38. (New) A method for the treatment of a human subject suffering from rheumatoid arthritis, said method comprising administering an effective amount of a compound as claimed in claim 1.

39. (New) A method for the treatment of a human subject suffering from osteoarthritis, said method comprising administering an effective amount of a compound as claimed in claim 1.

40. (New) A method for the treatment of a human subject suffering from dysmenorrhoea, said method comprising administering an effective amount of a compound as claimed in claim 1.